Ranbaxy Stability Testing System Draws FDA GMP Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA analysis of isotretinoin samples following a February inspection finds “lower potencies in these batches” before their expiration dates.
You may also be interested in...
Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from FDA's Import Alert
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.